Emergency Medications for Ventricular Fibrillation

Ventricular fibrillation (VF), also known as ventricular flutter, is one of the common causes of sudden cardiac arrest and sudden cardiac death. Ventricular flutter refers to rapid, regular, and continuous ventricular depolarizations occurring at a rate exceeding 240 beats per minute. In contrast, ventricular fibrillation occurs when the ventricles generate rapid, disorganized, and irregular electrical activity, with rates typically ranging from 250 to 600 beats per minute. So, what medications are used in the emergency management of VF? The following section addresses this question.

Emergency Pharmacotherapy for Ventricular Fibrillation

Ventricular fibrillation constitutes a form of cardiac arrest. Patients experiencing VF abruptly lose consciousness and central arterial pulses; apnea typically develops within one minute. Emergency management begins with immediate high-quality chest compressions. As soon as a defibrillator becomes available, deliver one shock (defibrillation) without delay. Immediately after defibrillation, resume chest compressions and provide rescue breaths. After two minutes of CPR, reassess the rhythm. If VF persists, deliver a second shock promptly, followed again by chest compressions and rescue breaths. Concurrently, administer intravenous epinephrine 1 mg. After another two minutes of CPR, reanalyze the rhythm. If VF remains, deliver a third shock, then continue chest compressions and rescue breaths while initiating antiarrhythmic therapy—such as amiodarone or lidocaine. For amiodarone, administer an initial intravenous bolus of 300 mg; if ineffective, give a second dose of 150 mg. For lidocaine, administer an initial intravenous bolus of 1.0–1.5 mg/kg; if needed, a second dose of 0.5–0.75 mg/kg may be given.

Supplementary Information: Causes of Tachycardia

1. Pathological Factors

Certain cardiovascular conditions—including coronary artery disease and hypertension—may cause tachycardia. Additionally, non-cardiac disorders such as anemia or hepatic disease can also lead to elevated heart rate. Patients with severe symptoms should seek prompt medical evaluation and treatment to prevent disease progression.

2. Pharmacological Factors

Sympathomimetic agents—including ephedrine and epinephrine—as well as parasympatholytic drugs—such as atropine, thyroid hormone, and amphetamines—can induce tachycardia. Moreover, chronic consumption of stimulant-containing beverages (e.g., those with caffeine, alcohol, or nicotine) may elevate blood pressure and accelerate heart rate due to their excitatory effects on the cardiovascular system.

3. Psychological Factors

During periods of intense anxiety or stress, respiratory rate increases significantly. To meet heightened metabolic demands, heart rate must likewise accelerate—resulting in tachycardia. Similarly, vigorous physical exertion places the body in a state of heightened sympathetic activation and physiological stress, thereby triggering tachycardia.

The above outlines key principles regarding pharmacologic management of ventricular fibrillation in emergency settings. We hope this information proves helpful.